Search

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

199.06 -1.06

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

195.88

Max

204.39

Belangrijke statistieken

By Trading Economics

Inkomsten

-239M

275M

Verkoop

-213M

4.2B

K/W

Sectorgemiddelde

25.073

62.58

EPS

2.9

Winstmarge

6.625

Werknemers

93,000

EBITDA

-239M

808M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+9.76% upside

Dividenden

By Acuity

Volgende Winsten

28 jul 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

6.7B

34B

Vorige openingsprijs

200.12

Vorige sluitingsprijs

199.06

Nieuwssentiment

By Acuity

41%

59%

110 / 340 Rangschikking in Healthcare

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 jul 2026, 19:06 UTC

Social Media

Shares of IQVIA Holdings Inc are lower following disappointing first-quarter results. Unusual call options activity exceeding $2 million indicates heightened investor interest.

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

9.76% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 223.8 USD  9.76%

Hoogste 249 USD

Laagste 200 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

12

Buy

1

Hold

0

Sell

Sentiment

By Acuity

110 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat